22 completed, 7 terminated, 5 unknown, 4 withdrawn. 17 Phase 4, 10 Phase 3, 7 Phase 1, 5 Phase 2, 3 Not applicable.
Follow Diovan: new trials by email Literature Review of Diovan trials Research Report on Diovan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High - Type 2 Diabetes, High Blood Pressure | Phase 1 / Phase 2 | Withdrawn | ARKAY Therapeutics | 2026-12-10 | 2026-07-16 | |
| Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction Sacubitril-valsartan, Valsartan - Heart Failure With Preserved Ejection Fraction, Myocardial Fibrosis | Phase 4 | Withdrawn | Brigham and Women's Hospital | 2026-08-27 | 2026-08-31 | |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Repurposing Valsartan May Protect Against Pulmonary Hypertension Valsartan 40 mg, Placebo - Pulmonary Arterial Hypertension, Right Heart Failure | Phase 2 | Recruiting | University of Washington | 60 | 2024-02-28 | 2026-05-04 |
| Sacubitril/Valsartan Versus Valsartan in Heart Failure With Improved Ejection Fraction Sacubitril-Valsartan, Valsartan - Heart Failure, Systolic | Unknown | Samsung Medical Center | 100 | 2021-03-16 | 2021-08-18 | |
| Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? Losartan, Valsartan, Azilsartan - Covid19, SARS-CoV Infection | Phase 3 | Terminated | University of British Columbia | 341 | 2020-10-09 | 2023-02-16 |
| Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension Sacubitril/Valsartan, Valsartan - Hypertension | Not applicable | Unknown | LanZhou University | 264 | 2020-07-09 | 2021-03-16 |
| The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans Sacubitril-Valsartan Tab 97-103 MG, Valsartan 160mg, Placebo Oral Tablet - PreDiabetes, Impaired Glucose Tolerance | Phase 4 | Active not recruiting | Ohio State University | 90 | 2020-02-25 | 2025-08-11 |
| Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition Sacubitril/Valsartan 200mg (blinded), Valsartan 160mg (blinded) - Diabetes Mellitus, Type 2, Pre-diabetic | Phase 3 | Withdrawn | University of Pennsylvania | 2018-06-01 | 2026-09-21 | |
| Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802 Valsartan, Ezetimibe/Rosuvastatin - Healthy Male Volunteers | Phase 1 | Completed | LG Chem | 42 | 2018-05-28 | 2019-02-15 |
| EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study) LCZ696, valsartan, LCZ696 placebo - Heart Failure | Phase 4 | Completed | Duke University | 365 | 2017-03-02 | 2021-12-03 |
| Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients placebo/valsartan - First Time Dual Chamber Pacemaker Implantation | Phase 4 | Terminated | Medical University of Silesia | 88 | 2017-01-01 | 2023-04-12 |
| Bariatric Surgery and Pharmacokinetics of Valsartan Valsartan - Obesity, Morbid | Recruiting | Norwegian University of Science and Technology | 12 | 2016-11-02 | 2026-08-13 | |
| Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy Hydroxychloroquine Sulfate, Valsartan - Primary IgA Nephropathy | Phase 4 | Unknown | Peking Union Medical College Hospital | 98 | 2016-06-01 | 2017-09-20 |
| Chronopharmacology of Valsartan in Normotensive Subjects Valsartan - Healthy Normotensive Volunteers | Phase 1 | Completed | Ain Shams University | 24 | 2015-11-01 | 2017-08-16 |
| Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients valsartan, Placebo - HIV, Aging | Not applicable | Terminated | Wake Forest University Health Sciences | 1 | 2014-07-01 | 2018-08-28 |
| Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM Valsartan, Placebo - Hypertrophic Cardiomyopathy | Phase 2 | Completed | Carelon Research | 211 | 2014-03-01 | 2021-01-11 |
| A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension Fimasartan, Valsartan - Essential Hypertension | Phase 2 | Completed | Boryung Pharmaceutical Co., Ltd | 75 | 2013-05-01 | 2014-09-08 |
| 24 Hour Ambulatory Cardiac Oxygen Consumption Nebivolol, Valsartan, Nebivolol/valsartan combination - Hypertension | Phase 3 | Completed | State University of New York at Buffalo | 26 | 2013-02-01 | 2025-06-08 |
| Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R), Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1), Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1) - Hypertension, Hyperlipidemia | Phase 1 | Completed | LG Life Sciences | 60 | 2012-12-01 | 2013-08-07 |
Showing 20 of 43. Sign in to see all of them.
Hypertension (19) · Diabetes Mellitus, Type 2 (4) · Heart Failure (4) · Essential Hypertension (2) · Glomerulonephritis, IGA (2) · Glucose Intolerance (2) · Hyperlipidemias (2) · Insulin Resistance (2) · Obesity (2) · Acute Kidney Injury (1) · Albuminuria (1) · Arthritis (1) · Autoimmune Diseases (1) · COVID-19 (1) · Cardiomyopathies (1)
Boryung Pharmaceutical Co., Ltd (3) · LG Life Sciences (2) · Novartis (2) · Novartis Pharmaceuticals (2) · State University of New York at Buffalo (2) · ARKAY Therapeutics (1) · Ain Shams University (1) · Ajou University School of Medicine (1) · Astellas Pharma Inc (1) · AstraZeneca (1) · Bayer (1) · Baylor Research Institute (1) · Brigham and Women's Hospital (1) · Carelon Research (1) · Columbia University (1)
United States (17) · South Korea (6) · Japan (4) · Taiwan (3) · Canada (2) · China (2) · France (2) · Poland (2) · Belgium (1) · Brazil (1) · Chile (1) · Denmark (1) · Egypt (1) · Germany (1) · Guatemala (1)
Alessandro Rossi, MD (1) · Byung-He Oh, Professor (1) · Byung-He Oh, professor (1) · Carolyn Y. Ho, MD (1) · David W Wray, Ph.D. (1) · Dong-Soo Kim, Professor (1) · Eugene Braunwald, MD (1) · Ewa Nowalany-Kozielska, MD PhD Associate Professor (1) · Gi-Sik Kim, professor (1) · Hiroaki Matsubara, MD,PhD (1)
PMID 10639539, PMID 11897754, PMID 11937179, PMID 12135313, PMID 12493255, PMID 14581662, PMID 14656957, PMID 15879332, PMID 16448896, PMID 16476843, PMID 17179034, PMID 17253471, PMID 17337887, PMID 17485598, PMID 17510503, PMID 18268136, PMID 19628800, PMID 19723695, PMID 19817870, PMID 19850215, PMID 19996069, PMID 20228403, PMID 20838053, PMID 21183747, PMID 21316752, PMID 21597296, PMID 21762358, PMID 22995802, PMID 23107894, PMID 23334870, PMID 23932463, PMID 25092393, PMID 25858003, PMID 26116459, PMID 28912187, PMID 31813281, PMID 32641226, PMID 34543161, PMID 34556856, PMID 34730769, PMID 35772853, PMID 37672268, PMID 38299639, PMID 39087355, PMID 39325643, PMID 40042824, PMID 40340372, PMID 41390047, PMID 42858009, PMID 9220209
K23DK117041 (1), K23HL168163 (1), P50HL112349 (1), R01HL065193 (1), R61HL167848 (1), U01HL084904 (1)